503A traditional compounding pharmacies: Cannot legally compound semaglutide (shortage resolved). Patients receiving compounded semaglutide from 503A pharmacies after mid-2024 are receiving a product the FDA considers illegally compounded. This does not mean it is unsafe in every case — quality varies by pharmacy — but it means there is no regulatory oversight ensuring quality, potency, or sterility.
503B outsourcing facilities: Face the same prohibition but some continue to fight it via legal challenges; some 503B facilities argue their products are "essentially a copy" which is still prohibited; legal and regulatory status remains contested as of 2026 with active litigation.
Telehealth providers: Telehealth companies (Hims & Hers, Ro, LifeMD, etc.) that prescribe compounded semaglutide are operating in an uncertain legal environment; some have shifted to tirzepatide compounding (tirzepatide shortage status differs); some continue offering compounded semaglutide via 503B partnerships while legal challenges proceed; patients should verify current legal status with their telehealth provider.
| Factor | Brand (Ozempic/Wegovy) | Compounded Semaglutide |
|---|---|---|
| FDA approval | Yes — full NDA approval with clinical trials | No — not FDA-approved; each batch not individually reviewed |
| Active ingredient | Semaglutide sodium, confirmed by manufacturer QC | Typically semaglutide acetate (different salt) or may be mislabeled; potency not independently verified unless pharmacy does testing |
| Potency guarantee | ±10% of labeled dose (FDA manufacturing standard) | No guarantee; FDA found wide potency variation in inspected compounded products |
| Sterility | Validated sterile manufacturing process | Depends entirely on individual compounding pharmacy's practices; PCAB accreditation is a positive signal but not equivalent to FDA manufacturing standards |
| Stability/shelf life | Validated stability data; established refrigeration requirements | Stability data typically not available for compounded formulations; may degrade faster than brand |
| Delivery device | Pre-filled auto-injector pen with dose dial; prevents dosing errors | Typically multi-dose vial + separate syringe; user must draw up dose; higher risk of dosing error, especially for patients unfamiliar with self-injection |
| Add-ons (legal concern) | Semaglutide only | Some compounders add B12, L-carnitine, NAD+, or other compounds — these combinations are not tested for safety, interaction, or efficacy; FDA views these as particularly problematic |
| Cost (monthly) | $900–$1,500 retail; often covered for T2D | $150–$400 via telehealth |
| Legal status 2026 | Legal; FDA-regulated | 503A: generally prohibited; 503B: contested; active litigation |
Manufacturer patient assistance (NovoCare): Novo Nordisk's NovoCare program offers Ozempic and Wegovy at reduced cost ($25–$99/month in some cases) for qualifying patients who are uninsured or underinsured; income requirements apply; apply directly at novonordisk.com/patient-assistance; this is the most underutilized legitimate cost-reduction pathway.
GoodRx and pharmacy discount programs: GoodRx, RxSaver, and pharmacy-specific discount programs can reduce Ozempic cost by 20–40% at certain pharmacies; prices vary significantly by pharmacy chain; worth comparing before filling; discount cards cannot be combined with insurance but can replace insurance for uninsured patients.
Tirzepatide (Zepbound/Mounjaro): Tirzepatide (Eli Lilly) is a dual GIP/GLP-1 receptor agonist with superior weight loss efficacy vs semaglutide (20–22% vs 15–18% body weight); compounded tirzepatide status differs — check current shortage status; Zepbound has its own direct-to-patient program (Zepbound Savings Card); may be available through telehealth with better legal standing than compounded semaglutide in 2026.
If using compounded semaglutide: If you are currently using compounded semaglutide and cannot access brand, minimize risk by: verifying your compounding pharmacy has PCAB (Pharmacy Compounding Accreditation Board) or ACHC accreditation; confirming they use USP-grade semaglutide API with certificate of analysis; starting at the lowest possible dose; being aware that you are using a product outside the current legal compounding framework; discuss transition to brand with your prescriber when financially feasible.